Haemophilus influenzae

Intravacc and DZNE awarded EU funding to develop vaccine against genetic ALS variant

Retrieved on: 
Wednesday, July 6, 2022
Diagnosis, C9orf72, Death, German Center for Neurodegenerative Diseases, Patient, Dementia, DPT, Influenza, Research, University, Brain, Bill & Melinda Gates Foundation, Man, Spinal cord, Paralysis, Union, Disease, ALS, Association, DZNE, Parkinson's disease, CDMO, Immune system, Infection, Motor neuron, Woman, Risk, Helmholtz Association, Neurodegeneration, Technology, Antibody, Nervous system, Neuron, Motor neuron disease, Human, Frontotemporal dementia, Pathology, Vaccine, Alzheimer's disease, Vaccination, Movement disorders, Mutation, WHO, Pharmaceutical industry, EU, Haemophilus influenzae

The project aims to develop the vaccine candidate identified at DZNE to the point where it can be clinically tested in humans.

Key Points: 
  • The project aims to develop the vaccine candidate identified at DZNE to the point where it can be clinically tested in humans.
  • About 5-10% of all ALS cases are caused by a mutation in the C9orf72 gene, making it the most common genetic ALS variant.
  • DZNE developed an experimental vaccine that instructs the immune system to produce antibodies against these harmful poly-GA molecules.
  • Clinical trials for C9orf72 ALS, which is the most common genetic variant of ALS, are expected to commence in 2025.

Intravacc and DZNE awarded EU funding to develop vaccine against genetic ALS variant

Retrieved on: 
Wednesday, July 6, 2022
Diagnosis, C9orf72, Death, German Center for Neurodegenerative Diseases, Patient, Dementia, DPT, Influenza, Research, University, Brain, Bill & Melinda Gates Foundation, Man, Spinal cord, Paralysis, Union, Disease, ALS, Association, DZNE, Parkinson's disease, CDMO, Immune system, Infection, Motor neuron, Woman, Risk, Helmholtz Association, Neurodegeneration, Technology, Antibody, Nervous system, Neuron, Motor neuron disease, Human, Frontotemporal dementia, Pathology, Vaccine, Alzheimer's disease, Vaccination, Movement disorders, Mutation, WHO, Pharmaceutical industry, EU, Haemophilus influenzae

The project aims to develop the vaccine candidate identified at DZNE to the point where it can be clinically tested in humans.

Key Points: 
  • The project aims to develop the vaccine candidate identified at DZNE to the point where it can be clinically tested in humans.
  • About 5-10% of all ALS cases are caused by a mutation in the C9orf72 gene, making it the most common genetic ALS variant.
  • DZNE developed an experimental vaccine that instructs the immune system to produce antibodies against these harmful poly-GA molecules.
  • Clinical trials for C9orf72 ALS, which is the most common genetic variant of ALS, are expected to commence in 2025.

Intravacc publishes 2021 annual report and announces expansion of its management team and board of directors

Retrieved on: 
Tuesday, July 5, 2022
MSD, Nycomed, Review, Master, Annual report, CEO, Biotechnology, Merck Sharp & Dohme Federal Credit Union, Wageningen, DPT, Influenza, Biology, University, Wageningen University & Research, Bill & Melinda Gates Foundation, Seattle University, Industry, CDMO, Master of Science, University College Utrecht, Infection, IT University of Copenhagen, Radboud University Nijmegen, Technology, PDF, Financial statement, Doctor of Philosophy, Board, Organon, Vaccine, Molecular biology, Director, WHO, Management, Pharmaceutical industry, EU, Haemophilus influenzae, Dome

In addition, Intravacc's Chief Financial Officer Nathalie Laarakker has been appointed to the board of directors.

Key Points: 
  • In addition, Intravacc's Chief Financial Officer Nathalie Laarakker has been appointed to the board of directors.
  • The annual report for the financial year 2021, including a review of figure, performance and Financial Statements for the Year ended 31 December 2021, is available online here and can also be downloaded as PDF.
  • A summary of Intravacc's financials are also published in the Annual Report Management of State Participations 2021 ( page 165-168, in Dutch ).
  • Furthermore, Intravacc B.V. is very pleased with the expansion of its management team and board of directors.

Intravacc publishes 2021 annual report and announces expansion of its management team and board of directors

Retrieved on: 
Tuesday, July 5, 2022
MSD, Nycomed, Review, Master, Annual report, CEO, Biotechnology, Merck Sharp & Dohme Federal Credit Union, Wageningen, DPT, Influenza, Biology, University, Wageningen University & Research, Bill & Melinda Gates Foundation, Seattle University, Industry, CDMO, Master of Science, University College Utrecht, Infection, IT University of Copenhagen, Radboud University Nijmegen, Technology, PDF, Financial statement, Doctor of Philosophy, Board, Organon, Vaccine, Molecular biology, Director, WHO, Management, Pharmaceutical industry, EU, Haemophilus influenzae, Dome

In addition, Intravacc's Chief Financial Officer Nathalie Laarakker has been appointed to the board of directors.

Key Points: 
  • In addition, Intravacc's Chief Financial Officer Nathalie Laarakker has been appointed to the board of directors.
  • The annual report for the financial year 2021, including a review of figure, performance and Financial Statements for the Year ended 31 December 2021, is available online here and can also be downloaded as PDF.
  • A summary of Intravacc's financials are also published in the Annual Report Management of State Participations 2021 ( page 165-168, in Dutch ).
  • Furthermore, Intravacc B.V. is very pleased with the expansion of its management team and board of directors.

Global Vaccine Market Analysis Report 2022-2027: Size, Forecasts, Industry Trends, Share, Growth, Insight, Impact of COVID-19, Company Analysis - ResearchAndMarkets.com

Retrieved on: 
Thursday, May 26, 2022
Health, Pharmaceutical, CSL Limited, Mumps, Infection, Pediatrics, Ebola, Measles, Prevalence, DPT, Janssen Pharmaceuticals, Chickenpox, Tetanus, COVID-19, Vaccination, Research, Immunization, Man, Diphtheria, Travel, HPV, Health, Death, DPT vaccine, Vaccine, Coronavirus, US, World Bank, Diagnosis, Cervical cancer, Awareness, Haemophilus influenzae, WHO, MMR, BCG, DTP, Meningitis, Ageing, Merck & Co., Inactivated vaccine, Patient, Bill & Melinda Gates Foundation, Industry, Insight, Sanofi Pasteur, Invention, GlaxoSmithKline, Hepatitis, Genetically modified bacteria, Pfizer, UNICEF, Pharmaceutical industry, Growth, Adult, Pneumonia, Haemophilus, Shingles, Rotavirus, Rubella

The "Global Vaccine Market, Size, Global Forecast 2022-2027, Industry Trends, Share, Growth, Insight, Impact of COVID-19, Company Analysis" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Vaccine Market, Size, Global Forecast 2022-2027, Industry Trends, Share, Growth, Insight, Impact of COVID-19, Company Analysis" report has been added to ResearchAndMarkets.com's offering.
  • Global Vaccines Market is anticipated to reach US$ 86.2 Billion by the year 2027 from $52.5 Billion in 2021.
  • The increasing consumer awareness of adequate immunization for killing various infections catalyzes vaccine market development.
  • Segmentation of Global Vaccines Market:
    In terms of end-user, the vaccine market is divided into pediatrics and adults.

Intravacc signs an exclusive license agreement with Zhifei Lvzhu Biopharmaceutical to commercialize Avacc 3 - an OMV based whooping cough vaccine

Retrieved on: 
Monday, May 2, 2022
Diarrhea, WHO, R, Protein, Antigen, OMV, Vaccine, Death, Infection, Fever, Tetanus, Shigellosis, Recombinant, Whooping cough, COVID-19, CHO, Bacteria, Pneumonia, Toxicity, Technology, University, Toxicology, Cough, China Biologic Products, Profile, Vomiting, SZSE, Meningitis, Respiratory disease, Marketing, Bill & Melinda Gates Foundation, Influenza, DTP, CDMO, Immunology, Diagnosis, Bordetella pertussis, DPT, Disease, Denis Favier, Pharmaceutical industry, Trevor Flugge, Diphtheria, Haemophilus influenzae

Under the terms of this agreement Zhifei Lvzhu will receive an exclusive license for the Chinese territory and non-exclusive for Africa, South America and selected Asian countries.

Key Points: 
  • Under the terms of this agreement Zhifei Lvzhu will receive an exclusive license for the Chinese territory and non-exclusive for Africa, South America and selected Asian countries.
  • Intravacc's Avacc 3, a homologous Bordetella pertussis candidate vaccine based on Intravacc's OMV platform, induces a strong systemic immune response.
  • Since 2008, over 110 million doses of vaccines producedby Zhifei Lvzhu have being given to people needed worldwide.
  • Zhifei Lvzhu is a wholly owned subsidiary of ChongqingZhifei Biological ProductsCo., Ltd. (SZSE: 300122, "Zhifei" for short), a leading vaccine supplier and service provider globally.

Intravacc signs an exclusive license agreement with Zhifei Lvzhu Biopharmaceutical to commercialize Avacc 3 - an OMV based whooping cough vaccine

Retrieved on: 
Monday, May 2, 2022
Diarrhea, WHO, R, Protein, Antigen, OMV, Vaccine, Death, Infection, Fever, Tetanus, Shigellosis, Recombinant, Whooping cough, COVID-19, CHO, Bacteria, Pneumonia, Toxicity, Technology, University, Toxicology, Cough, China Biologic Products, Profile, Vomiting, SZSE, Meningitis, Respiratory disease, Marketing, Bill & Melinda Gates Foundation, Influenza, DTP, CDMO, Immunology, Diagnosis, Bordetella pertussis, DPT, Disease, Denis Favier, Pharmaceutical industry, Trevor Flugge, Diphtheria, Haemophilus influenzae

Under the terms of this agreement Zhifei Lvzhu will receive an exclusive license for the Chinese territory and non-exclusive for Africa, South America and selected Asian countries.

Key Points: 
  • Under the terms of this agreement Zhifei Lvzhu will receive an exclusive license for the Chinese territory and non-exclusive for Africa, South America and selected Asian countries.
  • Intravacc's Avacc 3, a homologous Bordetella pertussis candidate vaccine based on Intravacc's OMV platform, induces a strong systemic immune response.
  • Since 2008, over 110 million doses of vaccines producedby Zhifei Lvzhu have being given to people needed worldwide.
  • Zhifei Lvzhu is a wholly owned subsidiary of ChongqingZhifei Biological ProductsCo., Ltd. (SZSE: 300122, "Zhifei" for short), a leading vaccine supplier and service provider globally.

CoBank Quarterly: War in Europe’s Breadbasket Upends Grain and Energy Markets, but Won’t Unwind Globalization

Retrieved on: 
Thursday, April 21, 2022
Knowledge, Water, Meat, Nitrogen, Fed, Farm Credit System, California Department, Plant-based diet, Farmer, COVID-19, Natural gas, Dairy, Transport, Federal Reserve, Soybean, GLOBE, Haemophilus influenzae, California Department of Water Resources, Livestock, Orange, Growth, Coal, Strategic Petroleum Reserve, Agricultural Market Information System, CoBank, Agriculture, Fertilizer, History, Poultry, Cotton, Policy, Citrus greening disease, Water resources, Industry, Federal, Joint, Risk, USDA, HPAI, 2016 Orange state by-election, Renewable energy, Milk, Gasoline, Q3, Biofuel

But the war will not diminish the need for global trade, which set a new record in 2021 at $28.5 trillion.

Key Points: 
  • But the war will not diminish the need for global trade, which set a new record in 2021 at $28.5 trillion.
  • Russias invasion of Ukraine roiled global grain trade and contributed to unprecedented price volatility in wheat, corn and soybeans during Q1.
  • Grain markets could remain volatile for two or more years due to disruptions in planting, harvesting, input application and transportation.
  • Feed supply challenges have been exacerbated by the risk to global grain stocks due to the war in Ukraine.

Physicians for Informed Consent Updates Its Information Statement About Vaccines and Immunocompromised Schoolchildren, Includes Data on COVID-19 Vaccines

Retrieved on: 
Monday, March 28, 2022
Risk, Virus, Family, MMR, Vaccination, Chickenpox, HPV, Measles, Public health, Parent, Friends, Poliovirus, Bacteria, Vaccine, TIV, Rubella, Environment, Immunodeficiency, PIC, Statistics, Influenza, Tetanus, Whooping cough, School, IPV, Diphtheria, LAIV, Safety, Mumps, Haemophilus influenzae, DPT vaccine, COVID-19, GLOBE, Hepatitis B, Science, Child, COVID-19 vaccine, Informed consent, Infection, Pharmaceutical industry, Physician

NEWPORT BEACH, Calif., March 28, 2022 (GLOBE NEWSWIRE) -- Physicians for Informed Consent ( PIC ), an educational nonprofit organization focused on science and statistics, has released an update to its information statement entitled "Vaccines: What About Immunocompromised Schoolchildren?"

Key Points: 
  • NEWPORT BEACH, Calif., March 28, 2022 (GLOBE NEWSWIRE) -- Physicians for Informed Consent ( PIC ), an educational nonprofit organization focused on science and statistics, has released an update to its information statement entitled "Vaccines: What About Immunocompromised Schoolchildren?"
  • Thus, informed consent and informed refusal in vaccination are both logical and moral, and there is no justification to mandate schoolchildren receive COVID-19 vaccines, or any other vaccines."
  • PIC delivers data on infectious diseases and vaccines, and unites doctors, scientists, healthcare professionals, attorneys, and families who support voluntary vaccination.
  • In addition, the PIC Coalition for Informed Consent consists of over 300 U.S. and international organizations.

STATEMENT ON HPAI IN JENNIE-O TURKEY STORE SUPPLY CHAIN

Retrieved on: 
Saturday, March 26, 2022
USDA, Minnesota Department of Commerce, Haemophilus influenzae, National Turkey Federation, Jennie-O, Farm, Food safety, Animal and Plant Health Inspection Service, Health, Minnesota Department of Agriculture, HPAI, Poultry

WILLMAR, Minn., March 26, 2022 /PRNewswire/ -- Jennie-O Turkey Store announced today that Highly Pathogenic Avian Influenza (HPAI) has been confirmed in its supply chain.

Key Points: 
  • WILLMAR, Minn., March 26, 2022 /PRNewswire/ -- Jennie-O Turkey Store announced today that Highly Pathogenic Avian Influenza (HPAI) has been confirmed in its supply chain.
  • While farms supplying turkeys to Jennie-O Turkey Store have not had any confirmed cases until now, many regions, producers and companies have been impacted since February.
  • Jennie-O Turkey Store has been preparing for this situation and took extensive precautions to protect the health of the turkeys in its supply chain.
  • USDA and the National Turkey Federation are monitoring and responding to the situation and remind consumers that HPAI does not pose a food safety concern.